Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine

International Journal of Infectious Diseases

Volumn 12, Issue 1, 2008, Pages 83-87

  Amini Bavil Olyaee, Samad ^a   Hosseini, Sayed Younes ^b   Sabahi, Farzaneh ^b   Alavian, Seyed Moayed ^c  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Genotype; Hepatitis B virus; Iran; Untreated patients; YMDD motif

Indexed keywords

DNA; LAMIVUDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GENE MUTATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; PREVALENCE; PROTEIN MOTIF; VIRUS HEPATITIS; YMDD MOTIF;

ADULT; AGED; AMINO ACID MOTIFS; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IRAN; LAMIVUDINE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PHYLOGENY; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA;

EID: 37349050634     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.05.001     Document Type: Article

References (27)

1. Kao J.H., and Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2 (2002) 395-403
2. Beasly R.P. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
3. Kramvis A., Kew M., and Francois G. Hepatitis B genotypes. Vaccine 23 (2005) 2407-2421
4. Mayerat C., Mantegani A., and Frel P.C. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection?. J Virol 6 (1999) 299-304
5. Kidd-Ljunggren K., Miyakawa Y., and Kidd A.H. Genetic variability in hepatitis B viruses. J Gen Virol 83 (2002) 1267-1280
6. Kidd-Ljunggren K., Myhre E., and Blackberg J. Clinical and serological variation between patients infected with different hepatitis B virus genotypes. J Clin Virol 42 (2004) 5837-5841
7. Lai C.L., Ching C.K., Tung A.K., Li E., Young J., Hill A., et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25 (1997) 241-244
8. Paik Y.H., Chung H.Y., Ryu W.S., Lee K.S., Lee J.S., Kim J.H., et al. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. J Hepatol 35 (2001) 92-98
9. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 (1998) 1670-1677
10. Kobayashi S., Ide T., and Sata M. Detection of YMDD motif mutation in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 34 (2001) 584-586
11. Huang Z.M., Huang Q.W., Qin Y.Q., He Y.Z., Qin H.J., Zhou Y.N., et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 11 (2005) 867-870
12. Amini-Bavil-Olyaee S., Sarrami-Forooshani R., Mahboudi F., Sabahi F., Adeli A., Noorinayer B., et al. Genotype characterization and phylogenetic analysis of hepatitis B virus isolates from Iranian patients. J Med Virol 75 (2005) 227-234
13. Amini-Bavil-Olyaee S., Sarrami-Forooshani S., Adeli A., Sabahi F., Abachi M., Azizi M., et al. Complete genomic sequences and phylogenetic relatedness of hepatitis B virus isolates in Iran. J Med Virol 76 (2005) 318-326
14. Eroglu C., Leblebicioglu H., Gunaydin M., Turan D., Sunbul M., Esen S., et al. Distinguishing hepatitis B virus (HBV) genotype D from non-D by a simple PCR. J Virol Methods 119 (2004) 183-187
15. Hosseini S.Y., Sabahi F., Amini-Bavil-Olyaee S., Alavian S.M., and Merat S. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains. J Virol Methods 137 (2006) 298-303
16. Rozanov M., Plikat U., Chappey C., Kochergin A., and Tatusova T. A web-based genotyping resource for viral sequences. Nucleic Acids Res 32 (2004) 654-659
17. Norder H., Courouce A.M., Coursaget P., Echevarria J.M., Lee S.D., Mushahwar I.K., et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47 (2004) 289-309
18. Miyakawa Y., and Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 46 (2003) 329-338
19. Huy T.T., and Abe K. Molecular epidemiology of hepatitis B and C virus infections in Asia. Pediatr Int 46 (2004) 223-230
20. Thakur V., Guptan R.C., Kazim S.N., Malhotra V., and Sarin S.K. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 17 (2002) 165-170
21. Thakur V., Sarin S.K., Rehman S., Guptan R.C., Kazim S.N., and Kumar S. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol 24 (2005) 12-15
22. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., et al., Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
23. Ye X.G., Wang R.L., and Guo H.B. Detection and analysis of YMDD mutated genes in patients of chronic hepatitis B before being treated. Zhonghua Jianyan Yixue Zazhi 25 (2002) 248
24. Yan M.H., Zhang C., Ling Q., and Zhou R.F. Detection of YMDD motif mutations in lamivudine-untreated patients with chronic hepatitis B. Zhonghua Ganzangbing Zazhi 11 (2003) 430-431
25. Heo J., Cho M., Kim H.H., Shin Y.M., Jang H.J., Park H.K., et al. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci 19 (2004) 541-546
26. Horgan M., Brannigan E., Crowley B., Levis J., and Fanning L.J. Hepatitis B genotype and YMDD profile in an untreated Irish population. J Clin Virol 35 (2006) 203-204
27. Tacke F., Manns M.P., and Trautwein C. Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance-implications for novel antiviral strategies. Curr Med Chem 11 (2004) 2667-2677